Long non-coding RNA GAS5 expression in patients with Down syndrome

Area of Science:

• Genetics
• Molecular Biology
• Developmental Biology

Background:

• Down Syndrome (Trisomy 21) is the most common chromosomal abnormality, leading to intellectual disability.
• Common features in Down Syndrome include inflammatory diseases, autoimmune conditions, and apoptosis, potentially linked to specific gene expressions.
• Long non-coding RNA (lncRNA) GAS5 has been implicated in inflammatory and autoimmune diseases.

Purpose of the Study:

• To investigate the expression profile of lncRNA GAS5 in individuals with Down Syndrome compared to controls.
• To determine if GAS5 expression is altered in patients with Trisomy 21.

Main Methods:

• Quantitative reverse transcription PCR (qRT-PCR) was used to measure lncRNA GAS5 levels.
• RNA sequencing experiments were performed to confirm qRT-PCR findings.
• The study included 23 patients with Down Syndrome and 23 age-matched controls.

Main Results:

• A significant down-regulation of lncRNA GAS5 was observed in patients with Down Syndrome.
• RT-PCR analysis and RNA sequencing data consistently showed reduced GAS5 levels in the DS group.

Conclusions:

• The down-expression of lncRNA GAS5 may play a role in the pathogenesis of typical features associated with Down Syndrome.
• Specifically, reduced GAS5 levels could be involved in the development of inflammatory and autoimmune diseases in DS patients.